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RESUMEN
En este trabajo se desarrollaron dos métodos simples y 
rápidos para la determinación de candesartán cilexetil en 
formas farmacéuticas que contienen este fármaco como 
monodroga. Candesartán cilexetil es una profármaco que 
se hidroliza a candesartán durante el proceso de absor-
ción gastrointestinal. Candesartán es un antagonista se-
lectivo (AT1) de los receptores de angiotensina II usado 
para el tratamiento de la hipertensión arterial. 
El método HPLC utiliza una columna Chromolith RP-18e 
y una fase móvil compuesta de acetonitrilo – solución 
acuosa de ácido trifluoroacético 0,1% en una proporción 
al  50,0: 50,0 (v/v), bajo un flujo isocrático.  
El método espectrofotométrico UV-derivativo se basa en 
la relación lineal existente entre la concentración de fár-
maco y la medición de la derivada de la señal espectrofo-
tométrica. Soluciones acuosas alcalinas de (NaOH 0,1 M) 
de candesartán cilexetil presentan un máximo a 246 nm 
y un mínimo a 263 nm (1D 246-263). La suma de estos dos 
valores absolutos es utilizada en el rango de concentra-
ción entre 6,34 mg L-1 y 25,34 mg L-1. La exactitud medida 
como porcentaje de recuperación es de un 98,9%, con 
una desviación estándar de 0,76%. 
Ambos métodos fueron validados de acuerdo a paráme-
tros establecidos para especificidad, linelidad, precisión, 
exactitud, estabilidad y límites de cuantificación y detec-
ción. Estos métodos fueron aplicados para el ensayo de 
uniformidad de contenido de dos presentaciones comer-
ciales de comprimidos.
Palabras clave: Candesartán cilexetil, métodos analíticos, 
comprimidos.
SUMMARY
In this work, two simple and fast methods for the deter-
mination of candesartan cilexetil in pharmaceutical forms, 
having it as a sole drug, were developed and validated. 
Candesartan cilexetil is a prodrug hydrolyzed to candesar-
tan during absorption from the gastrointestinal tract. Can-
desartan is a selective AT1 subtype angiotensin II receptor 
antagonist used in the management of hypertension. 
The HPLC method uses a Chromolith RP-18e column. The 
mobile phase is acetonitrile - 0.1% trifluoroacetic acid aque-
ous solution in ratio 50.0: 50.0 (v/v) in an isocratic elution 
at a flow rate of 1.5 mL min-1. The diode array detector is 
operated at 251 nm, and column temperature is set to 20o C.
The UV-derivative spectrophotometric method is based in 
the linear relation between drug concentration and first-or-
der derivative spectrophotometric measurement. Alkaline 
aqueous solutions (0.1 M NaOH) of candesartan cilexetil 
exhibit a maximum at 246 nm and a minimum at 263 nm 
(1D 246-263). The sum of these two absolute values is the sig-
nal used on the range concentration 6.34 mg L-1 to 25.34 
mg L-1. The accuracy of the method, as mean recovery per-
cent, is 98.9 % and the relative standard deviation, 0.76 %. 
Both methods were validated according to parameters 
established for specificity, linearity, precision, accuracy, 
stability and limits of quantification and detection.  The 
limits of detection and quantification, chromatographic 
parameters and selectivity obtained are better than other 
published methods. These methods were applied for the 
content uniformity of solid dosage pharmaceutical forms 
of two commercial brands.
Keywords: Candesartan cilexetil, analytic methods, tab-
lets
RESUM
En aquest treball es van desenvolupar i validat dos mèto-
des senzills i ràpids per a la determinació de candesartan 
cilexetil en formes farmacèutiques que contenen aquest 
fàrmac com monodrogues.
 Candesartan cilexetil és un profàrmac hidrolitzat a can-
desartan durant l’absorció en el tracte gastrointestinal. 
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Candesartan és antagonista selectiu (AT1) dels receptors 
d’angiotensina II utilitzats per al tractament de la hiperten-
sió arterial. 
El mètode HPLC utilitza una columna Chromolith RP-18e 
i una fase mòbil composta de acetonitril - solució aquosa 
d’àcid trifluoroacètic 0,1% en una proporció al 50,0: 50,0 
(v / v) sota un flux isocràtic.
El mètode espectrofotomètric UV-derivatiu es basa en la 
relació lineal existent entre la concentració de fàrmac i 
la mesura de la derivada del senyal espectrofotomètrica. 
Solucions aquoses alcalines de (NaOH 0,1 M) de cande-
sartan cilexetil presenten un màxim a 246 nm i un mínim a 
263 nm (1D 246-263). La suma d’aquests dos valors absoluts 
és utilitzada en el rang de concentració entre 6,34 mg L-1 i 
25,34 mg L-1. L’exactitud mesurada com a percentatge de 
recuperació, és del 98,9% amb una desviació estàndard 
de 0,76%. 
Ambdós mètodes van ser validats d’acord amb paràme-
tres establerts per especificitat, linelidad, precisió, exacti-
tud, estabilitat i límts de quantificació i detecció. Aquests 
van ser aplicats per a lassaig d’uniformitat de contingut de 
dues presentacions comercials de comprimits. 
Mots clau: candesartan cilexetil, mètodes analítics, com-
primits. 
1. INTRODUCTION
Candesartan cilexetil is a prodrug of the active compound 
candesartan, which is generated upon hydrolysis during 
absorption, and later on metabolized to the inactive MII 
(CV-15959) (1). Candesartan is a selective angiotensin II 
type I receptor blocker (2) indicated in patients with chronic 
arterial hypertension (3, 4). 
The chemical structure of candesartan cilexetil is ( ± 
)-1-(cyclohexylxicarbonyloxy) ethyl 2 – ethoxy-1 –((2’ –(1H-
tetrazol-5-ilo)biphenyl-4-yl)methyl)-1H-benzimidazole-
7-carboxilate (Figure 1)  and this compound is a white 
crystalline powder with melting point 163 ºC. It is insoluble 
in water and slightly soluble in ethanol (5).
Fig. 1.  Structure of candesartan cilexetil
A literature survey reveals several methods for the deter-
mination of candesartan cilexetil in pharmaceutical prepa-
rations or in biological fluids. The techniques employed 
include spectrofluorimetry (6), liquid chromatography (7-8), 
HPLC with fluorometric detection (9-10), micellar electroki-
netic chromatography (11) and mass spectrometry (12, 13). A 
derivative spectrophotometric method was development 
by Charoo et al. using methanol-0.35% polysorbate 20 
in pH 6.5 phosphate buffer (1:9 v/v) as solvent (14). Also, 
Erk reported two methods for the simultaneous determi-
nation of candesartan cilexetil and hydrochlorothiazide in 
pharmaceutical preparations. One, using HPLC with pho-
todiode array detector (15) and another, based on derivative 
spectrophotometry (16). However, these latter spectropho-
tometric methods have serious inconveniences originated 
in solubility issues and/or in complexity of candesartan 
cilexetil solutions preparation. For this reason, and con-
sidering the wide use of spectrophotometers and HPLC 
in pharmaceutical control laboratories, derivative spectro-
photometric and HPLC methods were developed in this 
work to determine candesartan cilexetil - in an adequate 
and simple medium - having in mind its application to the 
content uniformity test.
The development and validation of novel and simple ana-
lytical methods is an important issue for the pharmaceuti-
cal industry (17). The validation provides a high degree of 
confidence in the quality control and production processes 
of the dosage forms developed (18). It is a mandatory prac-
tice in every laboratory of analysis in order to guarantee 
the quality of the products manufactured by the pharma-
ceutical industry (19).
The analytical techniques developed in this work were 
validated for its use in routine analysis of the solid phar-
maceutical products containing candesartan cilexetil. All 
the parameters involved in the validation of the analytical 
methodology (20), including the United State Pharmacopeia 
(USP 2010)(21) and International Conference on Harmoniza-
tion (ICH 2005) (22) guidelines were established for this drug. 
2. EXPERIMENTAL 
2.1. Instrumentation
The HPLC system consisted of a Waters 600 controller, 
helium degasser, column thermostat, quaternary pump 
and a Waters 996 photodiode array detector.    
UV-derivative spectrophotometric analysis was achieved 
on UV- Vis, Unicam UV 2 -  100 Spectrophotometer (Cam-
bridge, U.K.), equipped with 1 cm quartz cells and Vision 
software provided by the manufacturer. The samples 
were stirred in Ultrasonic bath, Transonic Digital Elma 
(Singen, Germany) and centrifuged in Centrifuge Heraeus 
Labofuge 400 (Hanau, Germany).
Measurements of pH were made with a pHmeter WTW 
Model pH 537 from Welheim, Germany.
2.2. Reagents and materials
Candesartan cilexetil standard 98.7% purity and excipi-
ents mixture (lactose, hydroxypropyl cellulose, polyethyl-
ene glycol, cornstarch, croscarmellose sodium, red iron 
oxide and magnesium stearate, USP grade) were obtained 
from Saval laboratories S.A. (Santiago, Chile) and used as 
received. Analytical grade sodium hydroxide reagent in 
pellets and HPLC gradient grade acetonitrile (99.9%) were 
purchased from Merck. Trifluoroacetic acid (99%) was 
supplied from Aldrich. Water was purified and bidistilled 
from quartz apparatus and passed through a Milli-Q sys-
tem from Millipore. 
Acid and alkaline solutions were prepared with hydrochlo-
ridric acid and sodium hydroxide from Merck. 
2.3. Preparation of standard and stock solutions 
Chromatographic method
Stock solutions of candesartan cilexetil for HPLC analysis 
were prepared by dissolving 50 mg of this compound in 25 
mL of acetonitrile to obtain a final concentration of 2 mg 
mL-1. All working solutions in acetonitrile were prepared 
daily by dilution of appropriate aliquots of the standard 
stock solution. These solutions were stored at 5o C and 
showed to be stable for at least 1 month.
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Candesartan cilexetil standard solutions plus excipients 
were prepared in acetonitrile. 8 (or 16) mg de candesar-
tan cilexetil standard and 324 (or 648) mg excipients were 
weighed and transferred into a 25 mL volumetric flask with 
acetonitrile as solvent.
Derivative spectrophotometric method
Candesartan cilexetil stock solutions (400 mg L-1 and 800 
mg L-1) in 0.1 M NaOH with or without excipient mixture 
were prepared from alkaline hydrolysis (0.1 M NaOH) of 
standard candesartan cilexetil. These solutions were pre-
pared by dissolving appropriate amounts of candesartan 
cilexetil standard in 30 mL of 0.1 M NaOH solution, trans-
ferred to a 100 mL volumetric flask and the volume com-
pleted with the same solvent.
Excipients solution: 1630 mg excipient mixture for cande-
sartan cilexetil tablets was transferred to a 100 mL volu-
metric flask and completed to volume with 0.1 M NaOH.
All solutions were stirred in an ultrasonic bath for 10 min-
utes, light protected, prepared daily and stored in a refrig-
erator in amber glass vessels.
2.4. Sample fortified preparation
Solutions of candesartan cilexetil standard solution plus 
excipients were prepared for HPLC and spectrophotomet-
ric analysis.  All solutions were prepared in a quadruplicate 
assay.
Chromatographic method
Mixture for 8 mg dose tablets: Aliquots of 10 mL of cande-
sartan cilexetil standard solution plus excipients for HPLC 
analysis were transferred to 25 mL volumetric flasks with 
acetonitrile as solvent. After centrifugation at 3500 rev min-
1 for 5 minutes, aliquots were taken from supernatant to 
prepare solutions of 8.00, 11.52, 14.09, 16.01, 20.49 and 
23.05 mg L-1 in acetonitrile.
Mixture for 16 mg dose tablets: Solutions of 7.97, 15.94 
and 22.95 mg L-1 were prepared with the same procedure 
previously described.
Derivative spectrophotometric method
Mixture for 8 mg dose tablets: Aliquots of 20 mL of cande-
sartan cilexetil solution plus excipients for spectrophoto-
metric analysis were transferred to 50 mL volumetric flasks 
and the volumes completed with 0.1 M NaOH solution. Af-
ter centrifugation at 3500 rev min-1 for 5 minutes, using 
supernatant, aliquots were taken for preparing solutions of 
220.37, 300.47, 381.24, 454.05, 530.90 and 611.50 mg L-1 
in 0.1 M NaOH.
Mixture for 16 mg dose tablets: Solutions of 150.50, 
350.20 and 530.00 mg L-1 were prepared with the same 
procedure described.
2.5. Analysis and measurements 
Chromatographic method
Aliquots of 20 μL of the standard solutions and samples 
were injected into the HPLC. Chromolith RP-18e (2 mm 
macropore, 10 cm × 4.6 mm i.d.) monolithic column from 
Merck was used as a stationary phase. Standard solution 
injections were interleaved during injection. The analysis 
was performed by setting the detector at the maximum 
of absorption, 251 nm.  All experiments were carried out 
at column temperature of 20oC. The mobile phase was a 
mixture of (A) aqueous solution of 0.1% trifluoroacetic 
acid and (B) acetonitrile (50: 50 v/v) in an isocratic elution 
mode was found to give optimal results. The mobile phase 
was degassed and filtered by passing through a 0.45 µm 
pore size membrane filter (Millipore) prior to use.  The flow 
rate of mobile phase was 1.5 mL min-1. The total time of 
analysis was 12 min. The diode array detector was set to 
monitor at a wavelength of 251 nm. 
Derivative spectrophotometric method
Zero-order absorption spectrum of candesartan cilexetil in 
0.1 M NaOH solution was obtained in the UV range 220-
320 nm at a scan speed of 1200 nm min-1, data interval 
1.0 nm and bandwidth 2 nm. The first derivative spectra 
were obtained by instrumental electronic differentiation 
(Savitzky-Golay algorithm on Vision software). In the pres-
ent method, we employed the absolute difference between 
the maximum at 246 nm and the minimum at 263 nm (1D 
246-263) expressed in arbitrary units (Figure 3).  In the zero-
order absorption spectrum, a rather small and unresolved 
band was observed centered at 251 nm, being unsuitable 
for analytical use. However, in the first-order derivative ab-
sorption spectrum, very clear bands are displayed at 246 
nm and 263 nm, appropriate as spectrophotometric signal 
for a quantitation method of candesartan cilexetil.
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Fig. 2.  First derivative spectrum of candesartan ci-
lexetil in 0.1 M NaOH solution (15.84 mg L-1)
2.6. Assay of pharmaceutical forms for content unifor-
mity test
Content uniformity was determined on tablets of unitary 
dose of 8 and 16 mg from two commercial brands.  Ten 
pharmaceutical forms of each unitary dose and commer-
cial brand were treated and analyzed.
Chromatographic method
Tablet nominal dose 8 mg (or 16 mg) was dissolved in 15 
mL of acetonitrile in an ultrasonic bath for 15 minutes at 
25oC and adjusted to 25 mL with the same solvent in a 
volumetric flask. The former solution was centrifuged at 
3500 rev min-1 for 5 minutes. The supernatant was filtered 
through a 0.45 µm membrane filter. Finally, 20 µL were in-
jected in triplicate into the HPLC system for the assess-
ment of drug content uniformity in each tablet. 
Derivative spectrophotometric method
A commercially available tablet of candesartan cilexetil 8 
mg (16 mg) was transferred to a 50 mL (100 mL) volumet-
ric flask and 20 mL 0.1 M NaOH solution was added. It 
was shaked in ultrasonic bath for 10 minutes at 25 ºC and 
then the same solvent was added to complete the volume. 
After shaking, a portion of the content from the flask was 
centrifuged at 3500 rev min-1 for 5 minutes. A 5 mL aliquot 
of the supernatant was transferred to a 50 mL volumetric 
flask and volume completed with 0.1 M NaOH. The 1D 246-
263 was measured. 
λ
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3. RESULTS AND DISCUSSION
3.1. Chromatographic analysis
Several columns were tested and satisfactory results were ob-
tained when separation was performed on Chromolith RP-18e (2 
mm macropore, 10 cm × 4.6 mm i.d.) column from Merck. 
A series of mobile phases with different composition (na-
ture and volume fraction of the organic eluent modifier, ef-
fect of pH and buffer concentration) at different tempera-
tures (15 - 45o C) were also tested.  The effect of flow rate 
on the chromatographic resolution was performed in the 
range between 0.5 – 2.0 mL min-1; the optimal conditions 
were obtained with 1.5 mL min-1 using isocratic conditions.
The best results were obtained using a mobile phase con-
sisting of acetonitrile - 0.1% trifluoroacetic acid 50.0 / 50.0 
(v/v). The asymmetry of candesartan cilexetil peak increased 
with acetic acid or orthophosphoric acid at the same con-
centration was used and the retention time increased when 
mobile includes a buffer pH was increased from pH 3 to 7. 
The column temperature was set at 20oC because the re-
sults obtained showed that temperature does not affect 
significantly the chromatographic efficiency. 
The optimal detection condition was obtained using a 
photodiode array detector set at 251 nm, corresponding 
to the maximum absorption wavelength. An inadequate re-
producibility of peak area and poor linearity were achieved 
monitoring at 210 or 271 nm.
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Fig.3. Chromatogram of candesartan 
cilexetil in acetonitrile monitored at 251 nm
Under these conditions, the retention time of candesartan 
cilexetil is 8.21 minutes. Figure 3 shows a typical HPLC 
chromatogram obtained with these optimal conditions.
Chromatographic performance data as retention factor (k´) 
and tailing were calculated. Retention factor (k’) was de-
fined as (tR – t0) / t0, where tR is retention time of peak (min) 
and t0 is void time (min). In the present method, the void 
time was 0.83 min. Retention factor in the range of 0.5 < 
k` < 20.0 is desired to clearly separate the first peak from 
void time and to avoid a higher retention time for the last 
band. Retention factor of 8.89 was found for candesartan 
cilexetil, indicating a satisfactory separation. Tailing is de-
fined as W0.05 / 2 tW, where W0.05 is peak width at 5% of peak 
height (min) and tW is distance between peak front and 
peak retention measured at 5% of the peak height (min). 
The tailing factor for candesartan cilexetil peak was 1.22. 
3.2. Selectivity, alkali and acid degradations
Selectivity is the capacity of the method to accurately mea-
sure the analyte response in the presence of potentially 
interfering sample components (excipients or degradation 
products) or by studying the absence of any interference 
in same chromatographic run. In this work selectivity was 
evaluated by exposing of the amount of candesartan cilex-
etil to stress conditions, such as HCl (0.1 and 1.0 mol L-1) 
and NaOH (0.1 and.1.0 mol L-1) in aqueous solutions for 5, 
10, 30 and 60 minutes at room temperature. The theoretical 
final concentration was 8 mg L-1.
All acid solutions prepared were turbid, which accounts 
for the insolubility of candesartan cilexetil in this medium. 
Moreover, all alkali solutions were soluble and have a similar 
absorption spectrum with minimal variation of the measured 
signal. However, the chromatogram of alkaline solutions 
shows the total disappearance of the peak corresponding 
to candesartan cilexetil and the appearance of two peaks 
of degradation products (Figure 4). This result shows the 
determination by derivative spectrophotometric method of 
alkaline hydrolysis product of candesartan cilexetil.
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Fig.4. Chromatogram of alkaline hydrolysis products of 
candesartan cilexetil in 0.1 M NaOH monitored at 251 nm
3.3. Linearity and range
The HPLC and derivative spectrophotometric methods 
were validated using the following performance criteria: 
linearity and linear range, sensitivity, intra-assay and inter-
assay precision, accuracy, limit of detection (LOD) and 
limit of quantitation (LOQ).
The linearity, linear range and sensitivity were established 
through the calibration curve obtained by triplicate analy-
sis of candesartan cilexetil at nine concentration levels in 
acetonitrile solutions. Linearity was demonstrated over 
the concentration range of  152.4 - 750 mg L-1.  The linear 
equation was obtained by least-squares linear regression 
analysis of the peak area of analyte standard in arbitrary 
units versus concentration (mg L-1):
Area candesartan cilexetil (A.U.) = 21441 x conc. candes-
artan cilexetil (mg L-1) + 112049
(1)
The correlation coefficient of the linear standard curve was 
0.9997.  The sensitivity is the slope of the calibration graph 
(21441 ± 7838 A.U. L mg-1). 
The linearity of the spectrophotometric response for can-
desartan cilexetil solutions in 0.1 M NaOH was tested in 
nine concentrations and 1D 246-263 was measured for each 
solution.  The results showed good linearity in the range of 
1.12 to 25.34 mg L-1 with a correlation coefficient equal to 
0.9994. The standard deviation of slope is 3.05 x 10-5 and 
standard deviation of intercept is 4.60 x10-4.  
Linear regression equation is: 
1D246-263 (A.U.) = 6.52 x10
-3 conc. candesartan cilexetil (mg 
L-1) + 3.58 x10-3 
(2)
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3.4. Precision
The intra and inter day precision expressed as the relative 
standard deviation (RSD) of peak area and retention time 
were evaluated for HPLC method. The analyses were per-
formed using ten solutions.  Each solution was analyzed 
in triplicate. Table 1 shows typically determined values 
obtained for a formulation with 217 mg L-1 of candesar-
tan cilexetil, the mean retention time, area response and 
the corresponding relative standard deviations. Relative 
standard deviations of retention times and area response 
for intra and inter day assay are 0.7 %, indicating a good 
instrument reproducibility for this method. 
Table 1. Reproducibility of retention times and peak 
areas of the candesartan cilexetil (217 mg L-1)
Sample Retention time (min) Area response (A.U)
1
2
3
4
5
6
7
8
9
10
8.16
8.19
8.27
8.17
8.21
8.27
8.31
8.17
8.15
8.23
4760723
4795876
4763792
4783541
4770487
4720875
4787393
4711103
4738902
4701753
Mean value
RSD (%)
8.21
0.7
4753445
0.7
For the UV derivative method, the precision was deter-
mined in solutions of 16 mg L-1. These solutions were pre-
pared from supernatant solutions obtained of candesartan 
standard solution plus excipients. Relative standard devia-
tion  was 0.76 % (n=10)  while the precision of the spectro-
photometric measurement was  0.19 %.  
3.5. Accuracy
The accuracy of the methods was evaluated from recov-
ery assays. Thus, known aliquots of standard candesartan 
cilexetil solutions were spiked into their corresponding ex-
cipients mixture (candesartan cilexetil solution plus excipi-
ents). Tables 2 and 3, summarizes the results from accuracy 
experiments for 8 and 16 mg dose tablets, respectively. 
The values obtained by the proposed HPLC method for 
8 mg at six different concentrations levels show a 
recovery between 99.7 and 99.8%  with <1.0 % R.S.D. For 
16 mg, percentage recovery was 99.3, 100.1 and 100.0.0% 
for 150.5, 350.2 and 530.0 mg L-1, respectively. 
Accuracy for spectrophotometric method, evaluated at 
different concentrations gave mean recovery percent-
age of 98.9 % (Table 2 and Table 3) which agrees with 
the criteria previously mentioned. The slope and the inter-
cept of the linear regression equation of actual concen-
tration (x) versus found concentration (y) were 0.9829 and 
0.093, respectively, with a correlation coefficient 0.9996. 
Parameters, slope and intercept do not significantly differ 
from 1 and 0, respectively, at the 95 % confidence inter-
val, indicating that systematic errors were not observed.14 
Therefore the excipients used in the preparation of the 
pharmaceutical form (lactose, hydroxypropyl cellulose, 
polyethylene glycol, cornstarch, croscarmellose sodium, 
iron oxide and magnesium stearate) do not interfere in the 
determination. 
Table 2. Recovery results of candesartan ci-
lexetil in mixture for 8 mg dose tablets
Actual
mg L-1
Founda
 mg L-1              RSD
Recoverya
        %             RSD
HPLC method
220.37 220.11 ± 1.96 0.9 99.8 ± 0.9 0.9
300.40 299.04 ± 2.65 0.9 99.7 ± 0.9 0.9
381.24 380.32 ± 2.43 0.6 99.8 ± 0.6 0.6
454.05 452.97 ± 3.72 0.8 99.8 ± 0.8 0.8
530.90 529.34 ± 3.93 0.7 99.7 ± 0.7 0.7
611.50 609.95 ± 4.92 0.8 99.7 ± 0.8 0.8
Derivative spectrophotometric method
8.00 7.93 ± 0.16 2.0 99.0 ± 2.0 2.0
11.52 11.43 ± 0.18 1.6 99.2 ± 1.6 1.6
14.09 13.90 ± 0.08 0.6 98.6 ± 0.6 0.6
16.01 16.02 ± 0.03 0.2 100.1 ± 0.2 0.2
20.49 19.96 ± 0.39 2.0 97.4 ± 2.0 2.0
23.05 22.89 ± 0.34 1.5 99.5 ± 1.5 1.5
a mean ± standard deviation of four determinations
Table 3. Recovery results of candesartan ci-
lexetil in mixture for 16 mg dose tablets
Actual
mg L-1
Founda
mg L-1             RSD
Recoverya
        %                 RSD
HPLC method
150.50 149.34 
± 0.89
0.7 99.3 ± 0.7 0.7
350.20 348.29 
± 1.73
0.5 99.5 ± 0.5 0.5
530.00 530.09 
± 1.29
0.2 100.0 ± 0.2 0.2
Derivative spectrophotometric method
7.97 7.94 ± 0.11 1.4 99.5 ± 1.3 1.4
15.94 15.98 ± 
0.17
1.1 100.2 ± 1.1 1.1
22.95 23.27 ± 
0.20
0.9 101.4 ± 0.9 0.9
a mean ± standard deviation of four determinations
3.6. Limits of detection and quantification 
The limit of detection (LOD) and limit of quantitation (LOQ) 
were separately determined at the signal-to-noise ratios of 3 
and 10, respectively, measured at the approximate retention 
time of the corresponding to candesartan cilexetil peak. Us-
ing HPLC method, a detection limit of 0.45 mg L-1 was ob-
served and 1.34 mg L-1 was determined for quantitation limit. 
Moreover, limit of quantitation was estimated for the spec-
trophotometric method, obtaining value of 1.12 mg L-1.
3.7. Content uniformity
Content uniformity was determined tablets of unitary dose 
of 8 and 16 mg from two commercial brands in accor-
dance with the requirements of USP for tablets.  Ten phar-
maceutical forms of each unitary dose and commercial 
brand were analyzed by both methods described above. 
The acceptance limit for drug content uniformity set by 
USP is 85%-115% and RSD less than 6%.  
The amount of candesartan cilexetil was obtained by in-
terpolation on calibration curve. However for derivative 
spectrophotometric method is necessary to consider the 
dilution factor.
mg candesartan cilexetil / dosage form  =  
(3)
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Slope : calibration curve 1D 246-263 versus Candesartan ci-
lexetil concentration (mg L-1) 
Intercept : calibration curve 1D 246-263   versus Candesartan 
cilexetil concentration (mg L-1)
Dilution factor:
d = 0.5 for 8 mg dose tablet
d = 1.0 for 16 mg dose tablet
Results from assay of candesartan cilexetil tablets are 
shown in Table 4. The amounts found of this drug from 8 
mg tablets (tablet A) by HPLC and derivative methods were 
7.95 ± 0.10 and 7.81 ± 0.10 mg, respectively.  Also, the 
values found for 16mg tablets (tablet C) are satisfactory.
In summary, the results obtained by both methods are 
relatively similar.
Table 4. Content uniformity in tablets of two 
commercial brands (A and B) for two nominal dose 
Tablets 8 mg (A and B) and tablets 16 mg (A)
Tablet mg / tablet
Declared
Tablet A
mg/ tablet
Found
Tablet B
mg/ tablet
Found
mg / tablet
Declared
Tablet C
mg/ tablet
Found
HPLC method
1 8 8.03 7.78 16 8.00
2 8 7.98 7.85 16 8.01
3 8 7.95 7.87 16 7.87
4 8 8.01 7.93 16 7.93
5 8 7.79 7.78 16 7.78
6 8 8.00 7.86 16 7.86
7 8 8.02 7.90 16 7.90
8 8 7.75 7.79 16 7.79
9 8 7.91 7.92 16 7.92
10 8 8.02 7.85 16 8.03
mean 7.95 ± 0.10 7.85 ± 0.09 16.00 ± 
0.10
RSD 1.3 1.1 0.6
Derivative spectropho-
tometric method
1 8 7.65 7.80 16 16.37
2 8 7.83 7.84 16 16.40
3 8 8.01 7.55 16 15.65
4 8 7.87 7.51 16 16.59
5 8 7.67 7.80 16 15.66
6 8 7.62 7.74 16 15.97
7 8 7.78 7.61 16 15.95
8 8 7.84 7.56 16 15.79
9 8 7.96 7.65 16 16.50
10 8 7.90 7.64 16 15.55
mean 7.81 ± 0.13 7.67 ± 0.13 16.04 ± 
0.39
RSD 1.7 1.5 2.4
4. CONCLUSIONS 
Two simple and fast methods were developed and validat-
ed for determining candesartan cilexetil in pharmaceutical 
forms, where it present as a single active. The methods 
described in this work yield a linear, reproducible, sensi-
tive, selective and precise response by using instrumenta-
tion currently available in control laboratories.
The HPLC method used an isocratic mobile phase and 
was operated with diode array detector at 251 nm.
The derivative spectrophotometric method proposed 
is rapid, clean, efficient and used 0.1 M NaOH, solution 
where candesartan cilexetil is completely soluble.
These methods present an optimal recovery and can be 
used to be applied for the content uniformity test in accor-
dance with the analytical quality parameters established 
by The United States Pharmacopoeia (USP) and Interna-
tional Conference on Harmonization (ICH) guidelines.
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